The recommendation of betula verrucosa is the first NICE approval for an under-the-tongue immunotherapy for these conditions. Unlike conventional treatments that merely mask symptoms, this ...

Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

Unstable angina and NSTEMI: early management Clinical guideline CG94 Published: 24 March 2010 Last updated: 01 November 2013 ...

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection Technology appraisal guidance TA761 Published: 19 January 2022 ...

Guidance by programme NICE guidelines (6) Review the evidence across broad health and social care topics. Technology appraisal guidance (2) Reviews the clinical and cost-effectiveness of new ...

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling ...

COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community NICE guideline NG163 Published: 03 April 2020 Last updated: 13 October 2020 ...